Project Grant R01CA287287
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research $323,860 through the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of mutagenic DNA repair mechanisms in cancer cell persistence and acquired drug resistance. The award, effective August 18, 2025, with a completion date of April 30, 2028, funds a research project examining how cellular stress from anti-cancer drugs rewires DNA...
- Summary: Transcript RNA-Mediated Mechanisms in End-Joining Repair of DNA Double-Strand Breaks Georgia Tech Research Corporation received a $607,227 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) effective July 1, 2026, through April 30, 2030. The award funds fundamental research to systematically investigate the role of transcript ribonucleic acid (RNA) in modulating repair of double-strand breaks...
- Grant Award Summary Beth Israel Deaconess Medical Center received a $524,110 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year project period (June 1, 2026 – May 31, 2031). The award funds research on one-ended DNA break repair mechanisms in mammalian cells, focusing on how cells manage error-free and error-prone homologous recombination at replication fork breaks and double-strand breaks. The research directly...
- The National Cancer Institute (NCI) awarded University of Massachusetts Medical School a $469,628 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, with a completion date of May 31, 2031. This five-year research initiative investigates fundamental mechanisms of BRCA1 protein function in DNA replication and lagging strand synthesis, with particular focus on how BRCA1-deficient cancers develop sensitivity to anti-cancer therapies. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), through its Cancer Research Manpower program (CFDA 93.398), awarded a $211,112 Project Grant to Harvard Medical School on August 14, 2025, with a completion date of March 31, 2029. This award funds basic research investigating the molecular mechanisms of DNA damage repair pathways critical to cancer treatment resistance. Specifically, the research determines the role of Replication Protein A (RPA), an essential...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $683,075 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective March 24, 2026 through February 28, 2031. The award supports basic research investigating the mitotic function of the protein 53BP1 and its negative regulator TIRR in maintaining genome stability and preventing cancer-related chromosomal abnormalities. The research project,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 to the New York Genome Center, Inc. (NYGC) under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, with an ultimate completion date of April 30, 2029. This Project Grant funds the development and validation of Paired-Break-Seq, a novel high-throughput single-cell multiomics sequencing technique designed to simultaneously analyze DNA double-strand breaks (DSBs), single-strand breaks (SSBs), and...
- Federal Project Grant Award Summary Stony Brook University, through The Research Foundation for the State University of New York, received a $532,553 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026, through June 30, 2031. This award supports research investigating the repair of temozolomide (TMZ)-induced DNA damage in transcribed genes, with application to glioblastoma (GBM) treatment. The...
- Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on June 16, 2026, with completion targeted for May 31, 2031. The grant funds fundamental research to elucidate the non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer (CRC). The research utilizes an innovative mouse model that replicates the stepwise acquisition of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $586,864 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026, through June 30, 2031. The award funds research to characterize genetic dependencies induced by loss of the Fanconi Anemia (FA) pathway, a critical mechanism for maintaining genome stability through DNA repair...
MAINTENANCE OF GENOME STABILITY IN 3D - SUMMARY CANCER CELLS HARBOR SIGNS OF GENOMIC INSTABILITY, INCLUDING GENOME REARRANGEMENTS, WHICH CAN CONTRIBUTE TO TUMOR DEVELOPMENT. FAITHFUL DNA REPAIR COMBATS THIS INSTABILITY AND IS A POWERFUL TUMOR SUPPRESSOR MECHANISM WHEREAS ERRONEOUS REPAIR LEADS TO PATHOLOGICAL OUTCOMES. THE INHERENT GENOMIC INSTABILITY OF CANCER CELLS MAKES THEM MORE VULNERABLE TO A HIGH DAMAGE BURDEN AND DNA DAMAGING THERAPIES ARE AMONGST THE MOST WIDELY USED AND MOST SUCCESSFUL CANCER THERAPIES. DNA REPAIR IS ENABLED WITHIN NUCLEAR COMPARTMENTS OR REPAIR DOMAINS. SPATIAL ORGANIZATION OF REPAIR FACILITATES BIOCHEMICAL REACTIONS, RESTRICTS REACTIONS TO SPECIALIZED COMPARTMENTS WHILE BRINGING DNA LESIONS IN CLOSE PROXIMITY, THUS FAVORING RARE ABERRANT GENOME REARRANGEMENTS. WE HAVE MADE INITIAL PROGRESS IN REVEALING THE MECHANISMS UNDERLYING THE 3D RE-ORGANIZATION OF THE GENOME FOLLOWING DNA DAMAGE. BASED ON OUR SEMINAL DISCOVERY OF MECHANICAL FORCES DRIVING THE 3D ARRANGEMENT OF THE GENOME FOLLOWING DAMAGE, WE PROPOSE TO BETTER UNDERSTAND THE MECHANISMS RESPONSIBLE FOR THE ASSEMBLY OF DNA REPAIR DOMAINS AND TO EVALUATE THE PHYSIO-PATHOLOGICAL CONSEQUENCES OF ASSEMBLING THESE DOMAINS FOLLOWING TREATMENT WITH CHEMOTHERAPEUTIC DRUGS. WE WILL ALSO EXPLORE THE CONNECTION BETWEEN DNA REPLICATION AND DNA REPAIR IN 3D. OUR STUDIES SHOULD REVEAL COMMON RULES GOVERNING THE ORGANIZATION OF DNA TRANSACTIONS IN 3D, WHICH IN TURN HAVE THE POTENTIAL TO IDENTIFY NOVEL VULNERABILITIES FOR THE MOST COMMON MODALITIES OF CANCER TREATMENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 6/23/26 | ||
| Not listed | $0 | 6/11/26 | ||
| Not listed | $0 | 6/11/26 | ||
| Not listed | $0 | 9/25/25 | ||
| Not listed | $0 | 9/5/25 |